Sökning: L773:1933 7213 >
Lecanemab, Aducanum...
Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease
-
- Söderberg, Linda (författare)
- BioArctic AB, Warfvinges Vag 35, S-11251 Stockholm, Sweden.
-
- Johannesson, Malin (författare)
- BioArctic AB, Warfvinges Vag 35, S-11251 Stockholm, Sweden.
-
- Nygren, Patrik (författare)
- BioArctic AB, Warfvinges Vag 35, S-11251 Stockholm, Sweden.
-
visa fler...
-
- Laudon, Hanna (författare)
- BioArctic AB, Warfvinges Vag 35, S-11251 Stockholm, Sweden.
-
- Eriksson, Fredrik (författare)
- BioArctic AB, Warfvinges Vag 35, S-11251 Stockholm, Sweden.
-
- Osswald, Gunilla (författare)
- BioArctic AB, Warfvinges Vag 35, S-11251 Stockholm, Sweden.
-
- Möller, Christer (författare)
- BioArctic AB, Warfvinges Vag 35, S-11251 Stockholm, Sweden.
-
- Lannfelt, Lars (författare)
- Uppsala universitet,Institutionen för folkhälso- och vårdvetenskap,BioArctic AB, Warfvinges Vag 35, S-11251 Stockholm, Sweden.
-
visa färre...
-
BioArctic AB, Warfvinges Vag 35, S-11251 Stockholm, Sweden Institutionen för folkhälso- och vårdvetenskap (creator_code:org_t)
- 2022-10-17
- 2023
- Engelska.
-
Ingår i: NEUROTHERAPEUTICS. - : Springer. - 1933-7213 .- 1878-7479. ; 20:1, s. 195-206
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Immunotherapy against amyloid-beta (A ss) is a promising option for the treatment of Alzheimer's disease ( AD). A ss exists as various species, including monomers, oligomers, protofibrils, and insoluble fibrils in plaques. Oligomers and protofibrils have been shown to be toxic, and removal of these aggregates might represent an effective treatment for AD. We have characterized the binding properties of lecanemab, aducanumab, and gantenerumab to different A ss species with inhibition ELISA, immunodepletion, and surface plasmon resonance. All three antibodies bound monomers with low affinity. However, lecanemab and aducanumab had very weak binding to monomers, and gantenerumab somewhat stronger binding. Lecanemab was distinctive as it had tenfold stronger binding to protofibrils compared to fibrils. Aducanumab and gantenerumab preferred binding to fibrils over protofibrils. Our results show different binding profiles of lecanemab, aducanumab, and gantenerumab that may explain clinical results observed for these antibodies regarding both efficacy and side effects.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)
Nyckelord
- Amyloid-beta species
- Therapeutic antibodies
- Lecanemab
- Aducanumab
- Gantenerumab
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas